Stacking LL-37 + BPC-157 — Chronic Infection Protocol Chronic infections persist not because the immune system lacks antimicrobial capacity. But because tissue damage, biofilm formation, and inflammatory cascades create…
Read articleKPV BPC-157 Protocol IBD Research — Clinical Evidence A 2019 study published in the Journal of Gastroenterology found that KPV (lysine-proline-valine), a C-terminal tripeptide fragment of α-MSH, reduced colonic inflamma…
Read articleStacking KPV BPC-157 IBD Research — What Science Shows Animal models of inflammatory bowel disease treated with KPV (lysine-proline-valine) combined with BPC-157 (body protection compound-157) demonstrate faster mucosal…
Read articleLL-37 BPC-157 for Chronic Infection — Peptide Mechanisms Most chronic infections persist not because antibiotics failed to kill the pathogen. But because the damaged tissue environment allows recurrent colonisation. Res…
Read articleKPV BPC-157 for IBD Research — Peptide Mechanisms Examined Research into KPV and BPC-157 for inflammatory bowel disease (IBD) has produced some of the most compelling preclinical evidence for peptide-based mucosal repai…
Read articleVIP Thymosin Alpha-1 for CIRS Research — Real Peptides Research teams investigating Chronic Inflammatory Response Syndrome (CIRS) consistently identify two peptides as central to immune pathway correction: Vasoactive In…
Read articleVIP Thymosin Alpha-1 Protocol CIRS Research (2026) Research from the Center for Research on Biotoxin Associated Illness has identified that approximately 75% of CIRS patients show persistent immune dysregulation even af…
Read articleThymosin Alpha-1 BPC-157 for Lyme Research | Real Peptides Researchers at Stanford's Lyme Disease Research Program documented a pattern in 2024 that shifted how the field thinks about chronic Lyme treatment: patients wi…
Read articleThymosin Alpha-1 Thymalin Protocol Thymus Research Research published in the International Journal of Immunopharmacology identified thymosin alpha-1 as a toll-like receptor 9 (TLR9) modulator capable of activating dendr…
Read articleThymosin Alpha-1 BPC-157 Protocol Lyme Research A 2022 pilot study from the Johns Hopkins Center for Lyme Disease Research examined immune markers in 42 patients with post-treatment Lyme disease syndrome (PTLDS). The pa…
Read articleStacking Thymosin Alpha-1 BPC-157 Lyme Research Findings Research published in the International Journal of Antimicrobial Agents found that Borrelia burgdorferi. The spirochete responsible for Lyme disease. Persists in …
Read articleStacking Thymosin Alpha-1 VIP Long COVID Research Research from Stanford's Long COVID initiative found that up to 68% of patients with persistent symptoms six months post-infection show measurable T-cell dysfunction. No…
Read articleThymosin Alpha-1 VIP Protocol Long COVID Research A 2025 observational cohort published in Frontiers in Immunology found that patients receiving combined thymosin alpha-1 and VIP therapy showed 42% improvement in fatigu…
Read articleThymosin Alpha-1 VIP Long COVID Research — Peptide Trials A 2024 Phase 2 trial at Yale School of Medicine found that thymosin alpha-1 (Tα1) reduced markers of T-cell exhaustion by 42% in long COVID patients after eight …
Read articleStacking Thymosin Alpha-1 Thymalin Thymus Research Protocols A 2023 study published in the Journal of Immunology Research found that combining thymosin alpha-1 (Tα1) with thymalin in aged mice restored thymic output to …
Read articleThymosin Alpha-1 & Thymalin for Thymus Research Research conducted at the Institute of Bioregulation and Gerontology in Saint Petersburg found that thymalin administration increased CD4+ T-cell counts by 47% in aged ani…
Read articleStacking Thymosin Alpha-1 LL-37 Immune Research A 2023 in vitro study published by researchers at the University of Naples found that co-administration of thymosin alpha-1 and LL-37 produced a 3.2-fold increase in neutr…
Read articleThymosin Alpha-1 LL-37 Protocol Immune Research Research from the University of Texas Medical Branch found that thymosin alpha-1 increased CD4+ and CD8+ T-cell counts by 40–60% in immunocompromised patients within 28 da…
Read articleCerebrolysin BPC-157 Protocol TBI Research — 2026 Studies A 2024 preclinical study published by researchers at the Department of Neuroscience, University of Belgrade, found that combining Cerebrolysin with BPC-157 in se…
Read articleStacking Cerebrolysin BPC-157 TBI Research — What Works The single biggest error in TBI peptide research isn't choosing the wrong compound. It's stacking them incorrectly. Cerebrolysin and BPC-157 operate through entire…
Read article